| Literature DB >> 34822491 |
Yanping Li1, Yuting Zheng1, Ye Zhang1, Yuanyuan Yang1, Peiyao Wang1, Balázs Imre2, Ann C Y Wong2, Yves S Y Hsieh2,3, Damao Wang1.
Abstract
Brown algae (Phaeophyceae) have been consumed by humans for hundreds of years. Current studies have shown that brown algae are rich sources of bioactive compounds with excellent nutritional value, and are considered functional foods with health benefits. Polysaccharides are the main constituents of brown algae; their diverse structures allow many unique physical and chemical properties that help to moderate a wide range of biological activities, including immunomodulation, antibacterial, antioxidant, prebiotic, antihypertensive, antidiabetic, antitumor, and anticoagulant activities. In this review, we focus on the major polysaccharide components in brown algae: the alginate, laminarin, and fucoidan. We explore how their structure leads to their health benefits, and their application prospects in functional foods and pharmaceuticals. Finally, we summarize the latest developments in applied research on brown algae polysaccharides.Entities:
Keywords: alginate; bioactivity; brown algae; fucoidan; laminarin
Mesh:
Substances:
Year: 2021 PMID: 34822491 PMCID: PMC8623139 DOI: 10.3390/md19110620
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Schematic diagram of the dry matter and carbohydrate composition of brown algae; data summarized from references [9,15,16,17].
Figure 2The structure of alginate and the potential applications of alginate oligosaccharides.
Figure 3Structures of laminarin.
Figure 4Structure and biological effects of fucoidan (A: Ascophyllum nodosum and Fucus vesiculosus; B: Saccharina japonica, adapted from literature [119,120,121]).
Monosaccharide composition, molecular weight, concentration, sulfation degree and anti-inflammatory mechanism of different fucoidans.
| Brown Seaweed | Monosaccharide Composition | Molecular Weight | Concentration | Sulphate Content (%) | Mechanisms | References |
|---|---|---|---|---|---|---|
|
| Fucose 73 mol%, | - | 19.35 ng/µL; 80.64 ng/µL | 14.5% | Inhibited COX-1 and COX-2 | [ |
|
| Polyphenols 3.9% | Mw > 30 kDa | 25–100 µg/mL | 12% | Decreased production of | [ |
|
| Fucose 79.49% | 104.3 kDa | 25 µg/mL | 30.72% | Decreased production of | [ |
|
| Fucose 59.3% | - | 50 mg/kg | 23.51% | Reduced the expression of | [ |
|
| Fucose 86.4 mol% | - | 25–100 µg/mL | 38.3% | Suppressed the expression of COX-2 and pro-inflammatory cytokines in LPS-induced | [ |
|
| Fucose 50.9% | - | 50 mg/kg;150 mg/kg | Reduced the COX-2 expression dose dependently | [ | |
|
| Fucose 77.9 mol% | - | 50–100 µg/mL | 39.1% | Reduced NO production | [ |
|
| Molar rate 1:0.03:0.02:0.04:0.2:1.2 for Fucose, Galactose, Mannose, Xylose, | - | 30–60 mg/kg | 27% | Inhibition of COX, hyaluronidase, and MAPK p38 enzymes. | [ |
|
| Fucose 30.9% | - | 4.0 mg/kg | 15.1% | Inhibition of neutrophil extravasation | [ |
|
| Fucoidan | - | 0–100 mg/mL | Inhibited the release of nitric oxide, IL-1b, TNF-a, prostaglandin E2 and monocyte | [ | |
|
| Fucose 210.99 mmol/g | - | 100 mg/mL | 38.99.4% | Inhibition of IL-1b, TNF-a, and reduction of IL-10, IFN-c in production LPS treated cells | [ |
|
| Fucose 25.77% | - | 5-100 μg/mL | 27.32% | Delayed the apoptosis and promote pro-inflammatory cytokine production in human neutrophils | [ |
|
| Fucose 39.8% | - | 50–100 μg/mL | 24.07% | Delayed the apoptosis and promote pro-inflammatory cytokine production in human neutrophils | [ |